Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edoxaban - Daiichi Sankyo Company

Drug Profile

Edoxaban - Daiichi Sankyo Company

Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; Lixiana OD; Roteas; SAVAYSA

Latest Information Update: 09 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
  • No development reported Venous thrombosis

Most Recent Events

  • 04 Sep 2019 Efficacy and adverse events data from the phase IIIb ENTRUST-AF PCI trial in Embolism (Prevention) and Stroke (Prevention) released by Daiichi Sankyo
  • 06 Jun 2019 Daiichi Sankyo completes the phase IIIb ENTRUST-AF-PCI trial for Embolism (Prevention) and Stroke (Prevention) in United Kingdom, Ireland, Netherlands, Germany, Lithuania, Spain, Austria, Hungary, Portugal, Belgium, Italy, South Korea, Serbia, Switzerland, Taiwan and Ukraine (PO) (NCT02866175)
  • 18 Mar 2019 Efficacy and adverse events data from the ELIMINATE-AF phase III in Atrial fibrillation released by Daiichi Sankyo Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top